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ABSTRACT OF THESIS 
 
 
 
 
 
DETERMING THE EFFECTS OF CD151 AND β1 ON TUMOR CELL 
ADHESION 
 
 
Previous studies have shown that the upregulation of CD151 and β1 is associated with 
poor prognosis in many cancers such as breast cancer. Studies have provided evidence 
that these proteins are associated with the adhesion and migration of tumor cells. In this 
study, a microfluidic flow chamber was utilized to determine how CD151 and β1 affected 
the firm and initial adhesion of metastatic breast cancer cells to a planar endothelial 
monolayer under shear stress. This system mimicked the adhesion of metastatic breast 
cancer cells to the endothelial cells of the circulatory system. CD151 and β1 increased the 
firm adhesion of metastatic breast cancer cells onto an endothelial monolayer when 
subjected to high shear stresses. CD151 and β1 increased the initial adhesion of metastatic 
breast cancer cells onto an endothelial monolayer. A transwell assay was utilized to 
determine how CD151 and β1 affected random migration through different matrixes and 
random transendothelial migration.  CD151 and β1 decreased the random migration of 
metastatic breast cancer cells through matrices. Additionally, background information is 
provided related to the metastatic cascade, how it can be modeled with microfluidics, and 
how CD151 and β1 have been known to effect cancer and metastasis.  
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Chapter 1: Introduction 
Despite the fact that Richard Nixon declared the war on cancer in 1971, cancer remains to 
be one of the leading causes of death. In particular, cancer metastasis remains poorly 
understood[1]. One important aspect of  understanding the metastatic cascade is to 
identify key surface proteins that are involved in the process. In the past decades, CD151 
and β1 shown to be upregulated in many cancer types such as breast, lung, and prostate 
and have been correlated with poor prognosis[2, 3]. However, how these proteins affect 
metastasis remains poorly understood[4-7]  
This is due to the use of animal models and traditional models that do not mimic the 
physiological conditions in humans. In recent years, microfluidic models have been 
utilized to mimic the conditions of the human body. These models implement human 
cells while maintaining shear that physiologically representative unlike traditional 
models[8].  
In the studies described here, a microfluidic flow chamber produced by Ibidi was utilized 
to study the adhesion of breast cancer cells to an endothelial monolayer. To study random 
migration, a Boyden chamber, more commonly known as a transwell assay, was utilized.  
The specific objects here were: 
1) To determine if CD151 and β1 decrease the firm adhesion of metastatic breast 
cancer cells onto an endothelial monolayer 
2) To determine if CD151 and β1 decrease the initial adhesion of metastatic breast 
cancer cells to an endothelial monolayer.  
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3) To determine how CD151 and β1 affect the random migration of metastatic breast 
cancer cells through either gelatin or basement membrane extract both when a 
endothelial monolayer was present or absent.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
 
Chapter 2: Background 
2-1 The Metastatic Cascade 
While cancer is the second leading cause of death in the United States, only ten percent 
of those deaths are caused by the primary tumor[9, 10]. The remaining ninety percent is 
caused by secondary metastases which are difficult to treat and detect [10, 11].  These 
secondary tumors are formed after a tumor cell has undergone the metastatic cascade 
which can be viewed in Figure 2-1. The first step in the metastatic cascade is the process 
of angiogenesis which is the vascularization of a tumor which is triggered by the 
upregulation of angiogenic factors and the down regulation of inhibitors of vessel 
growth[4, 12].  The tumor can be avascular for many years at which time it does not grow 
beyond a millimeter in diameter nor do metastases occur. However, once vascularization 
occurs, the tumor can grow quickly in size because it now has necessary nutrients and 
oxygen, and the tumor cells increase their ability to metastasize because  of the close 
proximity to the vascular[13-15].  Evidence of angiogensis’ role in metastasis can be 
found in studies that demonstrate that the occurrence of metastases in distant sites is 
correlated with the count of microvessels. In these studies, 49 patients with invasive 
breast carcinoma had specimen removed, and it was found that with each 10-microvessel 
increase in the 200 x field, there was a 1.59-fold increase in the chance of metastasis 
occurring. Once the vessel count exceeded  100 in the 200 x field, 100 percent of patients 
had secondary metastases[16].  It is also hypothesized that the release of degenerative 
enzymes during angiogenesis aids the escape of cancer cells from the primary tumor[15, 
16]. 
4 
 
The next step in the metastatic cascade is the tumor cell undergoing the epithelial to 
mesenchymal transition (EMT) in which the tumor cell will transition from an epithelial 
cell to a mesenchymal type cell[4]. There are three instances in which a cell can undergo 
the EMT. The first is during implantation, embryogenesis, and the development of organs 
in a fetus.  The second is associated with tissue regeneration and organ fibrosis. The final 
instance is associated with cancer progression and metastasis. It is believed that EMT-
inducing signals such as HGF, EGF, and TGF-β are responsible for the induction and 
activation of a series of transcription factors that control the EMT program[17]. The loss 
of E-cadherin in particular is vital to the process and leads to dramatic changes in the 
cells including a loss of intercellular adhesion ability which allows for detachment from 
the primary tumor, and the morphological change to a motile phenotype. The expression 
of matrix metalloproteinase during this transition aid in the digestion of laminin and 
collagen IV which are key components in the basement membrane. Changes to the matrix 
will then trigger a positive feedback loop which enhances a cell’s ability to proliferate 
and invade the matrix[4].   
After a tumor cell undergoes the EMT and detaches from the primary tumor, it can 
migrate to the vasculature where it can enter through the process of intravasation. After 
the cell intravasates, the tumor cell can circulate throughout the body. How a secondary 
site is located can be explained by two hypotheses. The first is the seed and soil 
hypothesis which was introduced by Paget in 1889. This hypothesis compares the tumor 
cell to a seed and the secondary site to the soil. He proposed that tumor cells preferred 
microenvironments in which they were most compatible in. He analyzed over 900 
autopsy records of cancer patients to justify this hypothesis. Forty years after the 
5 
 
introduction of the seed and soil hypothesis, Ewing proposed the mechanical hypothesis 
which states that the secondary site is selected when a tumor cell reaches a site in the 
vascular that diameter is smaller than the diameter of the cell. This process of getting 
lodged in the vasculature is physical occlusion. In the 1970s, research was performed 
showing that secondary sites are selected by a combination of these two events[4, 18]. In 
the studies described here, physical occlusion was not taken into account. Rather, the 
steps of interest are those that take place when the secondary site is determined by the 
seed and soil hypothesis.  
If the tumor cell survives the physical stress of the circulatory system, it will come into 
contact with the vessel wall at which point it will start rolling on the wall. This will occur 
in vessels with a diameter larger than the diameter of the tumor cell. The tumor cell can 
interact with the endothelial cells that compose the lining of the vasculature, and the 
tumor cell can adhere to an endothelial cell. This cell’s ability to adhere will depend on a 
variety of factors including the resident time which is depended on the shear force 
exercised on the cell and the adhesive forces on the ligand-receptor pairs between the 
cells. It is also depended on the frequency of the cell colliding with the membrane-bound 
receptors and the endothelial ligands[4]. 
The next step in the metastatic cascade is extravasation which is the rate limiting 
step[19]. In this step, the cancer cell migrates through the endothelial lining of the vessel 
and penetrates the supporting extracellular matrix. It is widely believed that the CXC-
chemokine ligand 12 (CXCL12) is associated with extravasation. This chemokine is 
secreted by stromal cells in distant organs and attract cells with the CXCR4 and CXCR7 
6 
 
receptors[20]. However, the complete mechanism of extravasation remains relatively not 
understood.   
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Figure 2-1: The steps of the metastatic cascade. A.) First, angiogenesis, or the 
vascularization of the tumor must occur. B) Angiogensis is followed by EMT and 
detachment from primary tumor. C.) After detachment, the tumor cell can then 
invade the circulatory system by a process called intravasation. D.)The tumor cell 
will then circulate in vasculature. E.) Once contact has been made, the tumor cell 
can then adhere to vessel wall. F.) After the tumor cell has adhered,  it will then 
migrate through the endothelial monolayer and penetrate the supporting matrix 
through a process called extravasation. G.) After exiting the vasculature,  a tumor 
cell can form a secondary tumor.  
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2-2 Microfluidic Models 
2-2.1 Pitfalls of Traditional Models 
The main reason that the metastatic cascade is still poorly understood is because of the 
models that have been utilized to study it. Traditional in vivo models such as rat and 
mouse models have poor imaging capabilities which makes it impossible to determine if 
tumor cell adhesion or tumor cell extravasation is the step that is being mainly effected 
by the protein or chemoattractant of interest because it is impossible to visualize the 
arrest of the tumor cell on the endothelial lining[20, 21]. An alternative to the tradition rat 
and mouse model is using a zebrafish whose endothelium are transparent. However, it is 
still impossible to preform tightly controlled parametric studies. It is also impossible to 
directly relate the effects to humans because the endothelial cells composing the vessels 
are not human cells, and therefore, the surface expression of proteins is not identical to 
that seen in humans. This leads to different tumor-endothelial cell interactions than those 
in humans[8, 20].  
The most common in vitro studies are static well plate studies. For adhesion studies, 
endothelial cells would be seeded into the wells and allowed to grow to confluence. Then, 
the endothelial cells are stimulated to express adhesion molecules before cancer cells are 
allowed to settle on the endothelial cells. After a given settling time, the cells are then 
subjected to shear through a series of washes[22, 23]. The problems with this assay is that 
the shear from the washes would not be physiologically representative, constant, known, 
nor consistent[23, 24]. It is also impossible to view the cells undergoing detachment[23, 
25].  Finally, only firm adhesion can be examined[25].  
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To adapt a well plate in order to study migration and extravasation, transwell inserts, also 
known as a Boyden chamber, are added. These are inserts that have a membrane on the 
bottom. Endothelial cells can be grown directly on the membrane or the membrane can 
be coated with a matrix such as Basement Membrane Extract onto which endothelial cells 
can be seeded.  Cancer cells are then placed in the transwell, and a chemoattractant in the 
bottom of the chamber. The number of cancer cells that migrate through the membrane to 
the bottom of the well can then be counted[20, 26]. However, it is impossible to tightly-
regulate the local micro-environment nor can studies be performed under flow[27, 28]. 
Finally, the Boyden chamber only allows extravasation to be visualized in a plane parallel 
to the endothelial monolayer making it impossible to visualize the cell to cell 
interactions[27, 29]. While these studies help understand trends in extravasation, these 
limitations must be kept in mind when they are being utilized.  
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Figure 2-2: Common models to study metastasis. A.) Tail vein injections into mouse 
and rat models. B.) Static well plate studies in which cancer cells are allowed to 
adhere to the monolayer. C.) Transwell assays in which cancer cells are allowed to 
migrate through the endothelial monolayer into a bottom chamber. 
 
 
 
 
 
 
 
 
 
 
A. 
B. C. 
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2-2.2 Benefits of Microfluidic Models 
In recent years, microfluidic models have been utilized to address many of these 
concerns. The assay that inspired the design of the earliest microfluidic models was the 
parallel plate flow chamber which was introduced in 1987[30]. This system, which can 
be viewed in Figure 2-3(a), was novel because it could be connected to a pump which 
would provide a stable and known shear making much more representative of the 
physiological conditions than traditional static studies. It consisted of a permanox slide 
which endothelial cells were grown on, a silastic gasket which separated the slide from 
the base, and two polycarbonate bases. One of the bases had an entry and an exit that 
connected to a flow system.  
In 2000, Moss et al. preformed work utilizing a parallel plate flow chamber to study the 
initial adhesion of breast cancer cells to an endothelial monolayer. Flow studies were 
performed in which cancer cells were flowed into the chamber and their ability to adhere 
to the monolayer was examined. Studies were performed in which the monolayer was 
stimulated with TNF-α which were compared to studies without stimulation. The two 
shear stresses chosen for studies was 0.25 and 1.0 dyne/cm
2
. The maximum amount of 
adhesion occurred at 0.25 dyne/cm
2
 with a stimulated monolayer, and no adhesion was 
viewed at 1.0 dyne/cm
2
 without stimulation[31].         
Moss et al. continued their work on adhesion by examining initial attachment versus firm 
attachment. For these studies, a metastatic and nonmetastatic breast cancer cell line were 
compared. For the initial adhesion studies, it was found that only at high shear stresses is 
do metastatic cells adhere more to the endothelial monolayer. For studies in which firm 
attachment was examined, there was no difference in detachment from the monolayer 
12 
 
except at 5 dyne/cm
2 
 where the metastatic cells were more adherent, and at 10 dyne/cm
2
 
where the nonmetastatic cancer cells were more adherent[25].         
However, with the invention of microfabrication technology such as photolithography, 
micro-scale flow chambers were able to be produced. These micro-scale, called 
microfluidic, flow chambers were better able to reproduce physiological conditions, and 
they required less resources due to their small size[32]. 
Examples of commercially produced microfluidic flow chambers are those produced by 
Ibidi. One of special interest is the Ibidi μ-Slide VI0.4 which can be viewed in Figure 2-
3(b). Each slide contains six channels for flow experiments. The ability to perform 
multiple experiments on a single slide makes it more resource friendly than the parallel 
plate flow chamber in which only one study could be performed per permanox slide. 
Each slide is sterile and treated with a cell culture coating which increases the 
consistency of the experiments. As can be seen in the comparison in Figure 2-3, unlike 
the parallel plate flow chamber, the Ibidi slide is also a single piece so the height of the 
chamber will be constant and there is no possibility of leakage.  
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Figure 2-3: Comparison of a parallel plate flow chamber (A.) and the Ibidi μ-slide 
VI
0.4
 (B.). 
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2-2.3 Determining Shear Stress in a Microfluidic Flow Chamber 
Shear force is defined by de Nevers as the force which tends to make one surface slide 
parallel to an adjacent force. To determine the shear stress on the surface, the force is 
divided by the area that is in contact as shown in Equation 1. While solids can resist these 
shear forces, fluids cannot. Once subject to a shear force, a fluid will move and keep 
moving as long as the force is applied.  
𝜏 =
𝐹
𝐴
                                                                                                                                                 (1) 
For Newtonian fluids, the shear stress can be described by Equation 2 which is Newton’s 
law of viscosity. This law states that the shear stress, 𝜏, is linearly proportional to the 
velocity gradient which is represented by 
𝜕𝑢
𝜕𝑦
. The slope of the line is the dynamic 
viscosity 𝜇. Fluids that do not follow this behavior are non-Newtonian fluids[33].  
𝜏 = 𝜇
𝜕𝑢
𝜕𝑦
                                                                                                                                           (2) 
The shear stress through a vessel that is inelastic, cylindrical, and straight can be 
computed by the Haagen-Posseuille equation in which 𝑄 is the volumetric flowrate and 𝑑 
is the diameter of the vessel. The Haagen-Posseuille equation is Equation 3[34].  
𝜏 = 32𝜇
𝑄
𝜋𝑑3
                                                                                                                                    (3) 
The channel in the Ibidi μ-slide is rectangular rather than cylindrical. Therefore, a 
hydrolic radius must be used. The hydraulic radius is allows a noncircular channel to be 
approximated as a cylindrical channel. The equation for the hydraulic radius is shown in 
Equation 4[33].  
15 
 
𝐻𝑅 =
(𝑎𝑟𝑒𝑎 𝑝𝑒𝑟𝑝𝑒𝑛𝑑𝑖𝑢𝑐𝑢𝑙𝑎𝑟 𝑡𝑜 𝑡ℎ𝑒 𝑓𝑙𝑜𝑤)
(𝑤𝑒𝑡𝑡𝑒𝑑 𝑝𝑒𝑟𝑖𝑚𝑒𝑡𝑒𝑟)⁄                                 
(4) 
Ibidi provided the equation used to calculate shear stress through the channel of the Ibidi 
μ-slide which is shown in Equation 5. The constant includes the hydraulic radius. The 
dynamic viscosity, 𝜇, must be in the units of 
𝑑𝑦𝑛𝑒∙𝑠
𝑐𝑚2
 and the flow rate, 𝑄, must in in the 
units of mL/min. The resulting shear stress is in the units of dyne/cm
2
. 
𝜏 = 176.1𝜇𝑄                                                                                                                                    (5) 
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2-3 CD151 and Cancer 
CD151 is a member of the tetraspanin family of proteins. These proteins are named for 
the fact that they contain four transmembrane domains. In addition to these 
transmembrane domains, their structure contains a short extracellular and an intracellular 
loop and a large extracellular loop. This large extracellular loop contains three α-helices 
and a variable region which contains protein-protein interaction sites. This protein can be 
viewed in Figure 2-4. Tetraspanins regulate a variety of cell functions including 
morphology, motility, and invasion[2]. In humans, CD151 is expressed by a variety of 
cells including nearly all epithelial, endothelial, and fibroblastic cells[35]. Its importance 
can be demonstrated that if a mutation of the gene for CD151 occurs, the result is a 
variety of disorders including a skin blistering disease, kidney disruption, and 
sensorineural deafness[36].  
CD151 was the first tetraspanin that was associated with cancer, and since this discovery, 
it has been found to participate in almost all stages of cancer progression and the 
formation of metastases[37, 38]. Its upregulation has been associated with many cancer 
types including breast, lung, endometrial, and prostate[5-7, 39, 40]. This upregulation is 
correlated with a poor prognosis[38]. One potential reason that CD151 could play a major 
role in progression of cancer is because it associates tightly with the integrins α3β1, α6β1, 
α6β4, and α7β1 which interact with laminin, a key component of the extracellular matrix. 
This interaction also allows CD151 to modulate integrin-dependent functions of the cell 
such as migration, signaling, and adhesion strengthening all of which play roles in the 
progression of cancer[2].  
17 
 
Yue et al. performed in vivo assays with BDX rats , a variation of the albino rat, in which 
the rats were injected with 1x10
6
 tumor cells. While when both control ASML, a highly 
metastatic mouse cancer cell line, and ASML-CD151 kd cells were injected thousands of 
metastasis formed, there was a delayed metastatic growth of ASML-CD151 kd cells 
compared to the controls in the lymph nodes. This indicates that CD151 is not required 
for the formation of metastases but increase the tumor cell’s efficiency to reach the lymph 
nodes since the CD151 kd cell line reached the lymph nodes but at  slower rate. In studies 
in which the adhesion to different matrices was examined, the ASML-CD151 kd cell line 
did not differ in matrix protein adhesion compared to the control ASML cell line. The 
ASML-CD151 kd cell line also did not differ in migration through a transwell 
membrane[41]. 
Studies performed by Yang et al. demonstrated that CD151 affects the ability of a 
mammary cell to invade and its motility in both nonmetastatic MCF-10A and MDA-MB-
231 cell lines[5]. Mobilization of cells into a gap was examined by scratching a gap in a 
confluent cell monolayer and observing how the cancer cells invaded the gap. For both 
cell lines the absence of CD151 reduced the mobilization by nearly 50%. CD151’s effect 
of invasion through a transwell insert was also examined. There was a 78% reduction in 
invasion for the MDA-MB-231 CD151 kd cell line. There was also a significant 
reduction in invasion for the J110 (a malignant mouse breast cancer) CD151 kd cell line. 
Showing that when CD151 is absent, there is an overall reduction in invasion for both 
cell lines. This study also indicated that CD151 kd MDA-MB-231 cells had a decreased 
ability to spread on laminin-1 when the α6 integrin was blocked and the cells were not 
stimulated with EGF. CD151 ablation was not shown to effect spreading on fibronectin. 
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EGF, phorbol 12-myristate 13-acetate (PMA), nor could insulin-like growth factor I 
overcome CD151 ablation in invasion or spreading. In vivo studies performed on nude 
mice, in which control MDA-MB-231 cells where injected and the cells expressed either 
shRNA (small hairpin RNA) or CD151 shRNA, Tumors expressing the control were 
detected at 8 to 9 weeks while the CD151 ablated cells did not appear until 11 to 12 
weeks. Tumor growth was also delayed when tumor cells were injected into mammary fat 
pads. There was no morphologic differences between the tumors formed[5].  
Takeda et al. examined how CD151 affected the first stage of metastasis which is 
angiogenesis[42]. Studies in which an aoritic ring was embedded into Matrigel showed 
that aortic rings from CD151-null mice had impaired microvascular sprouting by 35% 
after 4 days. Similarly, matrigel plugs that were implanted into CD151-null mice showed 
diminished vascularization after 7 days. When CD151-null mice were injected with 
Lewis lung carcinoma, LLC, cells, smaller solid tumors formed compared to the wild 
type mice. There was also a significant decrease in microvessel density. When a corneal 
micropocket assay was performed, the corneal vessels from CD151-null mice showed 
minimal bFGF-stimulated sprouting.  
In vitro studies showed that there was no significant difference between mouse lung 
endothelial cells, MLECs, ability to proliferate or adhere when derived from CD151-null 
or wild type mice. However, several cell functions were altered. The CD151-null cells 
had decreased spreading on Matrigel by 50 % and to a lesser extent on fibronectin and 
gelatin. The transwell migration of CD151-null MLECs toward bFGF (basic fibroblastic 
growth factor) was reduced when the wells were coated with Matrigel or gelatin, but 
there was not a reduction when fibronetin was the coating. Invasion through Matrigel was 
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also diminished by 50 % for the CD151-null MLECs. The CD151-null MLECs also had a 
diminished ability to grow cellular cables, and CD151-null MLEC spheroids had 
significantly shorter capliary0like sprouts than the wild type. These results allowed 
Takeda et al. to conclude that CD151 plays a critical role during angiogenesis[42].  
Takeda et al. continued their work on CD151 and metastasis by examining how 
metastasis occurred in CD15- null mice[43]. The murine cancer cell lines, B16F10, a 
melanoma cell line, and LLC were used for these experiments.  For in vivo experiments, 
B16F10 cells were injected into the tail veins, and there were fewer metastatic foci in the 
lungs of the CD151-null mice compared to the wild type after two weeks. The 
experiments were repeated with LLC cells, and the results were the same. The CD151-
null mice also had fewer metastases in the kidneys, peritoneum, and the ovaries. Size 
distributions were not different between the two genotypes. Further studies were 
performed where the number of metastases was counted at 6, 24, 48, and 72 hours. Fewer 
B16F10 cells were recovered from the CD151-null mice at all points. Blood was 
analyzed to determine if there was a rapid clearance in the CD151-null mice, and the 
percentage of B16F10 cells was not diminished in the blood of the CD151-null mice at 
48 or 72 hours. CD151-null mice did not differ in leukocyte engagement or did not show 
an increased tendency to undergo cell death.  
Takeda et al. also did a series of adhesion and transwell assays using MLECs derived 
from CD151-null mice or wild type mice. The B16F10 cells adhered significantly less to 
the monolayers of MLECs derived from the CD151-null mice both with and without the 
addition of TNF-α. The MLECS were grown on a matrix before being removed, and the 
cancer’s cell’s ability to adhere to this matrix was examined. B16F10 cells adhered 
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significantly less to the ECM derived from the CD151-null mice that suggests that the 
CD151-null endothelial cells create a deficiency in the ECM. Transwell studies showed 
that transendothelial migration  of B26F10 cells through a monolayer of CD151-null 
endothelial cells was diminished. When migration of B26F10 cells through a monolayer 
of keratinocytes, there was no significant difference between the wild type and the 
CD151-null mice indicating that the effects of CD151 ablation differs between cell 
lines[43]. 
Zijilstra et al. examined how the anti-CD151 antibody, mAB 1A5, affected intravasation 
and metastasis[38]. To determine if CD151 effected spontaneous metastasis, a chick 
embryo spontaneous metastasis assay was utilized. These animals contained either HEp3 
or HT1080 tumors, and were injected with mAB 1A5 or the control antibody mAb 29-7. 
The anti-CD151 antibody could inhibit spontaneous metastasis. Depsite HT1080 and 
HEp3 having different CD151 expression, the mAB 1A5 inhibited spontaneous 
metastasis in both. Experiments using SCID mice had similar results. This indicated that 
CD151 inhabitation occurred independently of tumor expression. 
Next, the migration of HEp3 cells through a matrix was examined. The mAB 1A5 
antibody inhibited migration through laminin. However, the antibody also reduced the 
level of migration through collagen and uncoated filters. It was suggested that the 
antibody enhanced the matrix interactions. To examine if CD151 effected extravasation 
and the subsequent formation of secondary tumors, the CAM model was used. HEp3 
cells in the presence and absence of mAb 1A5 adhered to the vasculature. Those not 
treated with the mAB 1A5 antibody disseminated throughout the CAM stroma. However, 
those treated with mAb 1A5 proliferated but failed to disseminate which suggested to 
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Zijilstra et al. that the antibody was preventing migration. In vivo studies in which HEp3 
cells were injected i.v. in the presence of the control or the anti-CD151 antibody showed 
that mAb 1A5 did not inhibit tumor cell arrest or growth as there were tumor cells found 
in the LCAM and the lung after four days for both  treatments. This indicates that the 
inhibition of migration plays a greater role in migration from the primary site than in the 
migration to the secondary site. When HEp3 or HT1080cells were injected into the CAM 
model, the animals that had been treated with mAB 1A5 had tumors with a defined 
boarder and little to no invasion of the surrounding stroma compared to the control 
animals that had an irregular invasive front on the tumor-stromal interface. When HEp3 
tumors were implanted into the CAM, it was found that mAB 1A5 inhibited migration 
velocity, but there was residual movement and the cells’ ability to change direction was 
unaffected. This inhibition was shown to be caused by the rear of the tumor cell not being 
able to detach. However, when CD151 was silenced with shRNA silencing, neither the 
migration nor metastasis was limited significantly. Further experiments using the CAM 
model showed that CD151 inhibition prevented intravasation which inhibits the 
subsequent metastasis[38].  
Deng et al. examined the effects of CD151 on transendothelial migration and migration 
through Matrigel[44]. The tumor cell line MCF-10A was the cancer cell line and Human 
Umbilical Vein Endothelial cells were chosen as the endothelial cell line. When no 
chemoattractant was present, there was no statistical difference in transendothelial 
migration between the knock down cell line and the control. The same was true when 
TGF-β was utilized as a chemoattractant. However, when stimulated with EGF, the 
CD151 knock down cell lines had a reduced migration by 50%.  When this study was 
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repeated to examine the effects of migration through Matrigel, CD151 knock down cells 
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Figure 2-4: The tetraspanin CD151. The name tetraspanin is derived from the four 
extracellular regions. There are also three loops- a short intera and extracellular 
loops and one large extracellular loop. 
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2-4 β1 and Cancer 
β1 is a member of the integrin family which are heterodimeric cell surface receptors. Each 
integrin consists of an α and a β subunit that are non-covalently bound[46, 47]. These 
subunits are transmembrane glycoproteins with large globular amino-terminal 
extracellular domains that bind to form an ellipsoidal head as can be viewed in Figure 2-
5[47]. There are eight different β subunits and 18 different α subunits which interact to 
form at least 22 different integrins with 10 of these containing β1[46, 48].  The primary 
function of β1 is to bind to laminin, but it can also interact with many of the other 
components of the extracellular matrix such as type IV and V collagen and 
fibronectin[47, 49]. This suggests that β1 potentially plays a large role in extravasation 
since a key step in extravasation is the tumor cell penetrating the extracellular matrix[4]. 
There have been examples in literature of β1 effecting metastasis. One study performed 
by Fijita et al. examined the effects of β1 on the invasion and metastasis of colorectal 
cancer. A total of 51 tissue samples of tumors and normal mucosa were acquired during 
surgeries and analyzed using an immunoblot assay.   Of these samples, the pre-β-unit was 
increased in 15 samples, and β1 was increased in two of the samples. Fifteen of these 
cases with altered expression had lymph node metastases while only 12 of the samples 
with unaltered expression had lymph node metastases suggesting that β1 expression plays 
a key role in the metastasis of colorectal cancer to the lymph nodes[50]. 
A second study was performed by Elliott et al. which utilized a murine model to 
determine how the Anti-β1 integrin IgG affected pulmonary macrometastases. One of two 
spontaneous intraductal mammary adenocarcinoma cell lines was injected into the 
mammary fat pad of the animals. The first cell line was SP1 and the second was its 
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metastatic sister line SP1-3M. Either the Anti-β1 antibody IgG or the control non-immune 
IgG was injected every two days. The Anti-β1 antibody suppressed the growth of overt 
macrometastases in the SP1 cell line with a significant reduction in the mean diameter of 
the nodules compared to the control group. However, metastatic tumors still formed 
suggesting that the β1 antibody impeded the formation of metastases after extravasation 
occurred[51].  
Cannistra et al. examined how β1 affected ovarian cancer. Flow cytometry showed that 
the β1 chain was widely expressed in the four ovarian cancer cell lines, CAOV-3, SKOV-
3, OVCAR-3, and SW626, that they were examining. When tumor samples were 
harvested from nine patients, all samples expressed the β1 chain. Adhesion studies were 
performed in which the cancer cells’ ability to adhere to different matrixes was tested. All 
cell lines had significant binding to collagen type I. The CAOV-3 and the SKOV-3 cells 
bound significantly to laminin and fibronectin. The OVCAR- and SW626 cells bound to 
laminin and fibronectin to a lesser extent. To determine who β1 affected these cells ability 
to adhere to the matrix, the 4B4 anti-β1 antibody was utilized. Binding of CAOV-3 cells 
to collagen was inhibited by the antibody. Binding to laminin was prevented by the anti-
β1 antibody, but not by antibodies for α2 or α6 which indicates that laminin binding is 
facilitated by β1. No inhibitory effect was observed when the cells bound to fibronectin. 
To determine if β1 was responsible for the binding of cancer cells to the peritoneal 
mesothelium, adhesion of CAOV-3 cells to confluent monolayers of mesothelial cells 
was examined when both the anti-β1 antibody was present or absent. The binding was not 
inhibited by the presence of the antibody suggesting that more than the β1 integrin effects 
the metastasis of ovarian cancer[52]. 
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Canninstra continued studying the effects of β1on ovarian cancer with Strobel. In these 
studies, the ovarian cancer cell lines 36M2, CAOV-3, and SKOV-3 were utilized. All of 
these cell lines widely expressed the β1 integrin. For these studies, the 4B4 and the 
MAB13 anti-β1 antibodies were utilized. As in the previous study, there was a minimal 
inhibitory effect of the 4B4 antibody on the binding of cancer cell lines to confluent 
monolayers of peritoneal mesothelial cells even at high concentrations of the 4B4 
antibody. However, when the MAB13 antibody was utilized, the binding was inhibited 
significantly in all cell lines. This suggests that the inhibitory effect is dependent on type 
of antibody used. The studies in which CAOV-3 ability to bind to fibronectin were 
repeated with both of the antibodies. The MAB13 antibody inhibited the binding of the 
CAOV-3 to a greater degree than the 4B4 antibody. When the cells were exposed to the 
RAT16 α5-integrin antibody, the binding of 36M2 and CAOV-3 to the mesothelium was 
inhibited suggesting that the α5β1 integrin is responsible for the binding of ovarian cancer 
to the mesothelium[53].  
Michelle Chen presented a poster in which the role of β1 in extravasation was examined. 
Here, when β1 was silenced in MDA-MB-231 cells, extravasation was reduced. It was 
determined to be partially caused by a reduced adhesion rate to the monolayer which was 
confirmed with flow studies on a planar monolayer[54].             
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Figure 2-5: A integrin containing the β1 subunit. The α unit and the β1 are 
transmembrane proteins that bind noncovalently to form an ellipsoidal head. 
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2-5 Mechanisms of Tumor Cell Adhesion and Migration 
Cell migration is allowed through a combination of adhesion, protrusion, and contraction. 
Adhesion forces are present at both the leading edge and the rear of the cell. There is an 
optimum amount of adhesive forces that allows for the fastest migration. This was 
demonstrated in a study by Gupton and Waterman-Storer in which epithelial cells were 
seeded on varying concentration of fibronectin. On low concentrations of fibronectin, the 
cells had few but dynamic adhesions. On high concentrations of fibroneticin, the cells 
had many but less dynamic adhesions. On medium concentrations, there were moderate 
adhesions with well-organized dynamic patterns of actin flow which gave rise to the 
highest migration rates. This trend can be viewed in Figure 2-6[55].  
Adhesion at the leading edge of the cell provides traction for the cell as protrusions form 
and also initiates signals that are responsible for the dynamics of migrations[56]. This is 
caused by the polarization of the cell due to external signals and results in the extension 
of a protrusion from the leading edge which is thought be caused by vesicle trafficking of 
adhesive molecules to the leading edge[56, 57]. The adhesive forces in the cell must be 
balanced appropriately. If the adhesive forces at the leading edge of the cell are too weak, 
the cell cannot pull forward. If the adhesive forces at the rear edge of the cell are too 
strong, the cell cannot detach from the substrate and move forward[58].  
Contractile forces caused by myosin motors work to help break adhesive interactions by 
the application of physical stress. Studies using fibroblasts suggest that during this 
process of the rear release, the majority of integrins are left on the substrate suggesting 
that these integrins play a major role in the attachment and detachment of the rear of the 
cell. Integrins can also be removed from the rear end of the cell by endocytosis. Once 
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endocytosis has occurred, the integrins can either accumulate in the cell or are transported 
to the cell front. This process is called integrin trafficking[57].  
Evidence has suggested that there are multiple pathways for β1 endocytosis. One such 
pathway is regulated by the AP-2 clathrin adaptor. This pathway involves the binding of 
AP-2 to the cytoplasmic tail of CD151 which associates with the integrin β1. The clathrin 
mediated pathway also includes the cargo-specific endocytic adaptor Numb which binds 
directly to the β integrin sub-units and interacts with components of the clathrin 
endocytic mechanism. There are also pathways which are not mediated by clarthrin. 
Examples of these pathways include the internalization of α2β1 mediated by PKC and 
caveolae and the internalization of αLβ1 through a cholesterol-sensitive pathway. These 
pathways are modeled in Figure 2-7[59]. 
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Figure 2-6: Trend in how adhesion strength to the substrate effects random 
migration. There is an optimum adhesion strength in which the migration is the 
fastest.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-7: The different pathways in which integrin can be endocytosed during 
integrin trafficking.  
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2-6 Interaction of CD151 and β1 
As stated previously, CD151 tightly associates with the laminin binding integrins. To 
support this, one of the laminin binding integrins, α3β1, has not been found present in 
any tissue or cell in the absence of CD151 association [60, 61]. CD151 forms a stable 
complex with this integrin and modulates the ligand-binding affinity of the integrin as 
well as shifting the conformational equilibrium position [60, 62, 63]. This complex can 
be seen in Figure 2-8. Studies have shown that CD151 and α3β1 will concentrate together 
at the leading edge of a migratory cell and at the rear of the cell immediately before 
retraction. This suggests that together, they establish front-rear polarity during migration 
[64]. It has also been demonstrated that this CD151-α3β1 complex is stable even when 
treated with the surfactant Triton X-100[63].  
Nishiuchi et al. performed studies to determine how the associate of α3β1 with CD151 
effects ligand-binding. Studies in which there was CD151-free integrin α3β1 and CD151-
bound integrin α3β1 in phosphatidylcholine liposomes were allowed to bind to laminin-
10/11 surfaces. Less CD151-free α3β1 liposomes bound to the laminin than CD151-bound 
α3β1 lipsomes showing that CD151 stabilizes this integrin and increases its potential to 
bind to laminin-10/11. To determine how the α3β1 association with CD151 affected the 
adhesion of cells, the mAB 8C3 antibody was utilized. This antibody induces dissociation 
of CD151 from the α3β1 integrin. When A549 lung carcinoma cells were pretreated with 
this antibody, there was less adherence to laminin-10/11 than in untreated cells. Knocking 
down the gene for CD151 also decreased adhesion to laminin-10/11. All of these suggests 
that CD151 association with α3β1 increases laminin binding[63]. Studies have also 
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indicated that the association of CD151 with α3β1 is a factor in the binding to laminin-5 
during tumor cell-stromal cell interactions [65].  
Integrins, especially β1, interact with CD151 in tetraspanin webs. Tetraspanin webs are 
described as assemblies of multimolecular signaling complexes at the cell surface. As the 
name suggests, the primary molecules are tetraspanins. However, many other molecules 
are included in this web including integrins, membrane receptors, and other signaling 
molecules. This web creates a tetraspanin enriched microdomin, TEM. Devbhandari et al. 
examined 57 molecules that are found within a tetraspanin web centered on CD151 and 
found that β1 had the highest Mascot score and showed that it was the second most 
abundant of the tetraspanin partners. In their studies, HCCLM3 cells were utilized 
because they had the highest expression of CD151 protein. Using immunofluorescence, 
they determined that CD151 and β1 co-localized on the plasma membrane. When CD151 
was silenced, the internalization of β1 was impaired which impeded migration. When β1 
was silenced in cells with high CD151 expression, the motility and invasiveness was 
impaired. However, in cells with low CD151 expression, there was no effect on motility 
and invasiveness. It should be noted that the cells with low CD151 expression, the 
motility and invasiveness had been low before gene silencing[66].  
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Figure 2-8: Association of α3β1 with CD151. This association enhances binding of the 
integrin to laminin. 
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Chapter 3: Experimental Materials 
3-1 Flow System 
μ-Slide VI0.4 ibidiTreat: #1.5 polymeter coverslip, tissue culture treated, sterilized (Cat. # 
80606) was obtained from Ibidi, USA (Madison, WI). Male lock stopcocks (Cat. # SI-
30600-04), 1/16 inch hose barb male luer (Cat. # EW-45505-00), and Tygon Lab Tubing, 
Non-DEHP, 1/8x3/16 in (Cat. # EW-07407-75) were obtained from ColeParmer (Vernon 
Hills, IL). Standard Pump 22 Infusion/Withdraw with standard syringe holder (Cat #. 
552226) was obtained from Harvard Apparatus. BD medical 20 mL syringes with leur-
lok tip (Cat #. BD302830) were obtained from VWR (Radnor, PA).  
3-2 Microscope and Camera Assembly for Adhesion Studies 
Axiovert 35 inverted microscope, AxioCam MRm (Cat. # 426509-9902-000), and 
AxioVision Softer AV 4.9.1 64 bit (Cat. # 4101330906000000) were obtained from Zeiss 
(Oberkochen, Germany). X-cite series 120Q was obtained from Exceliates Technologies 
(Miamisburg, OH).  
3-3 Treatment of HUVEC Cells  
3-3.1 HUVEC Culture 
HUVEC cells at passage 1 (Cat. # C2519A), EGM-2 SingleQuot Kit Suppl&Growth 
Factor (Cat. # CC-4176), EBM Basal Medium Phenol Red Free (Cat. # CC-3129) were 
obtained from Lonza (Basel, Switzerland).  
3-3.2 HUVEC Subculture 
HEPES-Buffered Saline Solution (Cat. # CC-5024), Trypsin Ethylenediaminetetraacid 
Acid, Trypsin/EDTA, in a balanced salt solution (Cat. # CC-5012), and Trypsin 
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Neutralizing Solution, or TNS, (Cat. # CC-5002) were obtained from Lonza (Basel, 
Switzerland).   
3-4 Treatment of MDA-MB-231 Cells 
3-4.1 MDA-MB-231 Culture 
All MDA-MB-231 cell lines were provided by Dr. Xiuvwei Yang (Dept. Pharmacology 
& Nutritional Sciences, University of Kentucky). Dulbecco’s Modified Eagle Medium, or 
DMEM, with high glucose, no glutamine, no phenol red (Cat # 31053-028) was obtained 
from ThermoFisher Scientific (Waltham, MA). This medium was supplemented with 
50,000 U of Penicillin Streptomycin, or Pen Strep, (Cat. #: 15140122) and 1mL of 
Fungizone Antimycotic (Cat.#  15290-018) to prevent contamination from occurring. 
These were obtained from ThermoFisher Scientific (Waltham, MA). The medium 
contained 2 mM L-glutamine (Cat. # 21051024) and 1 mM sodium pyruvate (Cat. # 
11360-070) which were obtained from ThermoFisher Scientific (Waltham, MA). The 
medium was supplemented to a final concentration of 20% with Premium Grade Fetal 
Bovine Serum, or FBS, (Cat. # 97068-085) which was obtained from VWR (Radnor, 
PA).  
3-4.2 MDA-MB-231 Subculture 
Trypsin-EDTA (0.25%/0.53 mM) in Hanks Balanced Salt Solution (Cat. # 30-2101) was 
obtained from American Type Cell Culture.  
3-5 Adhesion Studies 
Recombinant Human Tumor Necrosis Factor-alpha, or TNF-α, (Cat. # 210-TA-005) was 
obtaind from R&D Systems. Dextran from Leuconostoc mesenteroides (Cat. # D4876) 
was obtained from Sigma Aldrich (St. Louis, MO). 
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3-6 Staining Cells for Transwell Assay 
1,1'-Dioctadecyl-3,3,3',3'-Tetramethylindocarbocyanine Perchlorate, or DiI stain, (Cat. # 
D-282) and 3,3'-Dioctadecyloxacarbocyanine Perchlorate, or DiO, (Cat #. D-275) was 
obtained from ThermoFisher Scientific (Waltham, MA). 
3-7 Transwell Assay 
Corning HTS Transwell-24 well permeable supports (Cat. # CLS3396) and Gelatin from 
porcine skin (Cat. #G1890) were obtained from Sigma Aldrich (St. Louis, MO). 
PathClear Cultrex Basement Membrane Extract, or BME, (Cat. # 95036-780) was 
obtained from VWR (Radnor, PA).  
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Chapter 4: Experimental Methods 
4-1 Cell Culture 
HUVECs were utilized at passages five through eight. The HUVECs were cultured at 37 
°C and 5 % CO2 in EGM-2 which was changed every other day at minimum until the 
cells were confluent. 
Three different variations of the breast carcinoma cell line MDA-MB-231 were utilized. 
The control cell line had been transfected with the green florescent protein (GFP) tag to 
negate any effect the GFP tag had on adhesion in the kd cell lines. Cell lines of MDA-
MB-231 with the genes for CD151 and β1 were used as the test cell lines. The gene for 
either CD151 or β1 was knocked down using shRNA gene silencing which degrades the 
mRNA. This process was performed by Dr. Yang. A GFP tag was used to indicate if the 
gene had been successfully knocked down in an individual cell. All cancer cells were 
cultured at 37 °C and 5 % in DMEM which was changed every other day a minimum 
until cells were confluent. 
4-2 Adhesion Studies 
4-2.1 Preparation of Endothelial Monolayer 
Once the HUVECs reached confluency, the HUVECs were washed with HEPES and 
trypsinized. The cell suspension was then neutralized with TNS, spun down, and the 
supernatant removed before being resuspended and counted using a cellometer. Cells 
were then diluted with EGM-2 to reach the desired concentration, and 30 μL of cell 
suspension was seeded into the channels of an Ibidi μ-slide. The seeding density varied 
depending on when studies were going to be performed. The HUVECs were allowed to 
settle for thirty minutes before the reservoirs of the channels were filled with 60 μL of 
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EMG-2. HUVECs were cultured in the Ibidi μ-slide at 37 °C and 5% CO2 until the cells 
were confluent at which time, the monolayer was stimulated with 20 ng/mL of TNF-α. 
This stimulated important adhesion molecules such as ICAM-1 and PECAM-1. The cells 
were incubated with TNF-α for 4 hours before experiments were conducted.  
4-2.2 Preparation of Breast Cancer Cells 
A confluent flask of cancer cells were trypsinized, spun down, and the supernatant was 
removed. The cells were resuspended and counted using a cellometer. The cell 
suspension was then diluted to the desired concentration, 5.0 x 10
5 
cells/mL for 
attachment experiments and 1.25 x 10
6
 cells/mL for the detachment experiments. The 
cells were resuspended in a solution of dextran in EGM-2. The dextran solution had a 
concentration of 7.5 g per 100 mL.  
4-2.3 Experimental Set Up 
One syringe was filled with the cell suspension and a second syringe was filled with the 
solution of dextran in EGM-2.  For attachment experiments the cell suspension syringe 
was connected to the syringe pump while the syringe containing the dextran solution was 
connected to the line of tubing through a valve.  The tubing before the valve was filled 
with the dextran solution while the tubing after the valve leading to the pump was filled 
with the cell suspension. This was to minimize the number of cancer cells introduced into 
the chamber before flow. This set up was reversed for detachment experiments in which 
the tubing before the valve was filled with the cell suspension while the tubing after the 
pump was filled with the dextran solution. The tubing was connected to one of the 
reservoirs of the Ibidi flow chamber and a second piece of tubing was connected to the 
corresponding outlet reservoir. This second piece of tubing led to a waste reservoir. This 
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setup can be viewed in Figure 4-1.  The flow chamber was placed on top of the stage of 
an inverted microscope. The monolayer could be viewed on the desktop computer screen 
through use of a camera and the corresponding software. The flow chamber was taped to 
the stage to ensure that the same location could be viewed for the entire length of the trial 
as shown in Figure 4-2. 
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Figure 4-1: Syringe set up for adhesion studies.  
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Figure 4-2: Experimental setup for all flow studies.  
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4-2.4 Detachment Experiments 
To determine how the cancer cells firmly adhere to an endothelial monolayer, detachment 
studies were carried out in the Ibidi flow chamber. A suspension of cancer cells at a 
concentration of 1.25 x 106 cells/mL were introduced into the chamber through the 
secondary syringe. These cancer cells were allowed to settle on the endothelial 
monolayer for 30 min. After the cells were allowed to settle, initial bright field and 
florescent images were taken. The monolayer was then perfused for 1 minute at a flow 
rate of 0.01 mL/min to remove any nonadherent cancer cells, loose endothelial cells, or 
cell debris. Bright field and florescent images were taken again after this wash. The 
monolayer was then perfused at the flow rate required to produce the required shear of 
either 2 or 8 dyne/cm
2
 [25]. Final bright field and florescent images were taken. The 
wash and the 10 minute trial were recorded using the time lapse option on the Axiovision 
software. This consisted of the software automatically taking images very second.  
4-2.5 Attachment Experiments 
To determine how the cancer cells initially adhere to an endothelial monolayer, 
attachment studies were carried out in the Ibidi flow chamber. The front end of the line of 
tubing was filled with a dextran solution in EGM-2 through use of a secondary syringe 
and the primary syringe contained the cell suspension at a density of 5 x 105 cells/mL. 
Initial bright field and florescent images of the monolayer were taken. The suspension 
was perfused into the chamber at a shear stress of 0.25 dyne/cm
2 
 [25, 31]. Experiments 
were conducted for a total of 40 minutes. The trial was recorded using the time lapse 
option on the Axiovision software at a frame rate of one frame per second.   
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4-3 Random Migration Studies 
4-3.1 Matrix Coatings 
Six of the twelve transwell membranes were coated with 0.5% gelatin to ensure that cells 
would adhere to the membrane.  Enough gelatin to coat the membrane was added to the 
transwell before being placed in a 37 °C incubator for 2 hours before being allowed to 
dry at room temperature overnight[67]. The other six transwells were coated with BME, 
which unlike gelatin, contains laminin, the protein to which both CD151 and β1 bind to. 
After being thawed on ice, the 20 μL aliquot of BME was diluted with ice-cold sterile 
deionized water to 0.125 mg/mL. 150 μL was injected into the transwell before 50 μL 
was removed. This step ensured a uniform layer. The transwells were allowed to dry 
overnight[68].  
4-3.2 Preparation of Endothelial Monolayer 
Once the HUVECs reached confluency, the HUVECs were washed with HEPES and 
trypsinized. The cell suspension was then neutralized with TNS, spun down, and the 
supernatant removed before being resuspended and counted using a cellometer. The cell 
suspension was diluted with PBS to a concentration of 1 x 10
6
 cells/mL, and a working 
solution of DiI was added to 1 mL of the cell suspension. This cell suspension was 
incubated for 20 minutes at 37 °C before being wash three times was EGM-2. Using a 
cellometer, the cell suspension was measured, and the suspension was diluted to a 
concentration of 5 x 10
5
 cells/mL using EGM-2. 100 μL of cell suspension was added to 
tranwell inserts that had been precoated with the matrix. The transwells were placed in an 
incubator at 37 °C and 5% CO2 overnight. In the morning, the HUVECs were examined 
using a Nikon microscope. 
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4-3.3 Seeding of Cancer Cells into Transwells 
After checking the HUVECs in the transwells, a confluent flask of cancer cells were 
trypsinized, spun down, and the supernatant was removed. The cells were resuspended 
and counted using a cellometer. The cell suspension was then diluted to the desired 
concentration of 1.0 x 10
6
 cells/mL. For the knocked down cell lines, this concentration 
was based off of the GFP transfection rate. For the control cells, 1 mL of suspension was 
added to a working solution of diO and the cells were responded in PBS. This cell 
suspension was incubated for 20 minutes at 37 °C before being wash three times in 
EGM-2. Using a cellometer, the cell suspension was measured, and the suspension was 
diluted to a concentration of 1 x 10
6
 cells/mL using EGM-2. For all cell lines, the media 
had been removed from the transwell, and 100 μL of cancer cell suspension was added to 
each transwell. The transwells were placed in an incubator at 37 °C and 5% CO2 for 24 
hours. 
4-3.4 Imaging of Transwells 
The media was removed from the transwells and the wells before the transwells were 
washed twice with PBS. A fixing solution of 3.5% Formaldehyde was prepared, and 100 
μL was placed in the transwell, and 600 μL was placed in the well. After 2 minutes, the 
formaldehyde solution was removed, and the transwells were washed twice in PBS. 
Using a cotton swab, the cells were removed from the apical side of the transwell, and the 
transwell was placed on a coverslip. An inverted Nikon microscope was used to image 
the transwells. Five representative images were taken-one in the center and one in each 
corner. To analyze the images of cells, the NIS Basic Software package was used. The 
object count function was used with the intensity option. For all images, the clean option 
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was set to x1, and any objects smaller than 5 μm in diameter were assumed to be cell 
debris.  
4-3.5 Statistical Analysis 
A Two-Way ANOVA was utilized to determine the statistical significance of the results. 
For all studies, the first condition was cell line. For the flow studies, the second condition 
was time while for the transwell assay studies, the second condition was matrix coating 
with and without HUVECs. The pairs were compared using the Holm-Sidak method for 
pairwise multiple comparison procedures. The analysis was performed using SimgaPlot.  
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Chapter 5: Results and Discussion 
5-1.Detachment Results 
The  detachment of the MDA-MB-231 cell lines at 2 dyne/cm
2
 and 8 dyne/cm
2
 are shown
in Figure 5-1 and Figure 5-2. When a shear stress of 2 dyne/cm
2
 is applied to the cells,
there was no difference in the detachment of the cells for the control and the two knock 
down cell lines. However, when a shear stress of 8 dyne/cm
2
 is applied to the cells, the
CD151 kd and the β1 kd MDA-MB-231 cells detach to a greater degree than the control 
MDA-MB-231 cells. This indicates that low shear stresses, such as those found in the 
venous circulation, the cancer cells can compensate for the lack of CD151 and β1. 
However, the cells cannot compensate for the loss of either protein at high shear stresses. 
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Figure 5-1: Detachment of MDA-MB-231 cells from an endothelial monolayer when 
the monolayer is subjected to a shear stress of 2 dyne/cm
2
. N=6. Error bars 
represent SE. * indicates p-value < 0.05. 
 
 
Figure 5-2: Detachment of MDA-MB-231 cells from an endothelial monolayer when 
the monolayer is subjected to a shear stress of 8 dyne/cm
2
. N=6. Error bars 
represent SE. * indicates p-value < 0.05. 
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5-2 Attachment Results 
The attachment of the different MDA-MB-231 cell lines is shown in Figure 5-3. At a 
shear stress of 0.25 dyne/cm
2
, the control cell line had significantly greater attachment 
than the two knocked down cell lines. This indicates that CD151 and β1 effect initial 
attachment. With attachment studies it is postulated  cancer cells do not have a long 
enough residence time to invoke a  response would overcome the loss of CD151 and β1 
the adhesion proteins. It is also possible that since one of the proteins is absent, the two 
cannot associate to aid in adhesion. These results are the first that have examined how 
these proteins effect initial adhesion as static studies can only determine the effects on 
firm adhesion and in vivo studies do not have the capabilities to separate the two different 
types of adhesion into different studies. Chen et al. found that β1 kd MDA-MB-231 cells 
were less adhesive to an endothelial monolayer than the control MDA-MB-231 cells 
which is in agreement to the detachment experiments at 8 dyne/cm
2
 and the attachment 
experiments reported here[54].  
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Figure 5-3: Attachment of cancer cells to an endothelial monolayer the cancer cells 
are introduced at a flowrate that produces a shear stress of 0.25 dyne/cm
2
 on the 
endothelial monolayer. N=6. Error bars represent SE. * indicates p-value < 0.05. 
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5-3 Random Migration Results 
Transwell assays were performed to determine how CD151 and β1 effected random 
migration on different surfaces. Four different surface conditions were examined and the 
results were shown here in Figure 5-4. When cancer cells were seeded directly on gelatin, 
the control cancer cells migrated less than the CD151 kd and the β1 kd cancer cell lines. 
When a confluent monolayer of endothelial cells were introduced on the control cancer 
cells migrated less than the β1 kd cells. However, there was no significant difference 
between the migration of the control cells and the CD151 kd cells.  When cancer cells 
were placed directly onto basement membrane extract,  the migration for all cell lines 
was statistically different with the control cells migrating the least and the CD151 kd 
cells migrating the most. When an endothelial cell monolayer was introduced on the 
basement membrane extract, there was no statistical difference in migration flux.  
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Figure 5-4: Random migration flux of cancer cell through a 0.4 μm pore under 
various conditions.  N=12. Error bars represent SE. * indicates p-value < 0.05. 
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5-4 Discussion 
In the detachment studies, there was no significant difference in the detachment of the kd 
cell lines from an endothelial monolayer than the control at a low shear stress of 2 
dyne/cm
2
. However, at a higher  shear stress of 8 dyne/cm
2
, the kd cells detached 
significantly more than the control cells. This indicates that CD151 and β1 are crucial for 
firm adhesion at high shear stress such as those found in the arterial system but not at low 
shear stresses. Attachment studies determined that both CD151 and β1 play a significant 
role in initial adhesion since the attachment to the endothelial monolayer was 
significantly impaired when CD151 and β1 is knocked down.  The role of CD151 in 
adhesion to an endothelial monolayer was confirmed by Takeda et al. who demonstrated 
that cancer cells adhered less to CD151-null MLECs. These studies were performed in a 
static well plate so direct comparisons cannot be made only trends can be observed[43]. 
Chen et a. confirmed that β1 affected adhesion to a planar HUVEC monolayer under 
shear flow. It was determined that β1 kd cells had significantly decreased adhesion[54]. 
Ad stated previously, CD151 and β1 tightly associate to form complexes that are stable 
under even extreme conditions such as exposure to Triton-X. When either protein is 
absent, this complex cannot be formed which could be the cause in decrease in adhesion.  
In the migration studies,  both kd cell lines migrated more than the control cells when 
seeded directly on the matrix. When endothelial cells were seeded on the gelatin matrix 
before the introduction of cancer cells, only the β1 migrated more than the control cells, 
and when endothelial cells were seeded on the basement membrane extract, there was no 
difference in migration. As described earlier, the cell’s ability to migrate depends on the 
adhesive forces. CD151 and β1 interact to aid in laminin binding and binding to different 
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types of collagen. Since basement membrane extract contains both laminin and collagen 
IV and gelatin is a collagen based compound, the control cells should adhere more to 
these compounds to a greater extent than the kd cells which would decrease the migration 
rate of the control cells. When Deng et al. examined migration of MCF-10A cells through 
an endothelial monolayer when no chemoattractant was present, there was not difference 
in migration between the control cells and the CD151 kd cells which was in agreement to 
what was observed in these studies[44]. Figure 5-5 shows how our data fit into and adds 
to current literature.  
In conclusion, CD151 and β1 significantly affect firm adhesion of MDA-MB-231 cells to 
an endothelial monolayer at high shear stress but not low shear stresses. CD151 and β1 
affected the initial adhesion of  MDA-MB-231 cells to an endothelial monolayer. When 
CD151 and β1 was absent, MDA-MB-231 cells migrated to a greater amount through the 
either a gelatin or basement membrane extract matrix.  
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Figure 5-5: Summary of our results written in red and how it fits in with other research in the same area of interest. 
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• Strobel and Cannistra saw 
decreased adhesion of ovarian 
cancer cells onto peridontal 
mesothelium cells when the anti-
β1 antibody MAB13 was utilized 
• We observed an increase in 
detachment of CD151 kd and β1 
kd  MDA-MB-231 cells on a 
planer endothelial monolayer when 
subject to a shear stress of 8 
dyne/cm2 but not to a shear stress 
of 2 dyne/cm2 
Initial Adhesion: 
• We observed an decrease in 
attachment of CD151 kd and β1 kd  
MDA-MB-231 cells on a planer 
endothelial monolayer  
• Yang et al. observed decrease 
migration of MCF-10A cells 
through membrane for CD151 
kd cells when EGF was a 
chemoattractant 
• Deng et al. saw decreased 
migration through Matrigel for 
CD151 kd MCF-10A cells when 
EGF was present  but not when 
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random migration of CD151 kd 
and β1 kd MDA-MB-231 cells 
through BME and gelatin 
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migration of B16F10 cells when  
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when FCS was a chemoattacent 
• Deng saw decreased migration 
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when EGF was present but not 
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• We observed no difference in 
migration of CD151 kd MDA-
MB-231 cells through a HUVEC 
monolayer seeded on gelatin or 
BME 
5
4
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5-5 Future Work 
5-5.1 Determining the Effects of Shear on Extravasation 
The model that was used to study migration here was a static transwell assay. To gain a 
more comprehensive view on the effects of CD151 and β1 on tumor cell extravasation, a 
model that allows for the cells to be under shear stress needs to be utilized. An example 
of this type of model are microfluidic models such as those proposed by Jeon et al. and 
Zhang et al[8, 69]. As noted with the detachment studies reported here, cells will detach 
to different extents under different shear stresses. It is possible that when subjected to 
shear stress, a different pattern in migration will occur than that in the transwell assay.  
5-5.2 Investigating Alternate Cancer Cell Lines 
The chosen cell line for these studies was MDA-MB-231. This breast cancer cell line is 
referred to as a triple negative phenotype because it does not express ERα, PR, and 
HER2.  It has the classification of Caudin-low[70]. This cell line is one of the most 
commonly used metastatic breast cancer cell lines for in vitro studies. It is possible that 
an underlying characteristic of the MDA-MB-231 cell line is effects how the cancer cells 
adhere and migrate when CD151 or β1 is absent. Therefore, these studies should be 
repeated with alternate cell lines. One option would be to look at a breast cancer cell line 
that is not triple negative for example MDA-MB-453 which does not express ERα or PR 
but is positive for HER2. Another would be to examine the effects on a different cancer 
such as the hepatocellular carcinoma cell line HCCLM3 which has been shown to have 
very high expression of CD151. 
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5-5.3 Investigating Alternate Endothelial Cell Lines 
HUVECs, as denoted by the name, are an endothelial cell line harvested from the 
umbilical cord vein. Endothelial cells will take on different morphologies and 
configuration depending on their location in the circulation meaning that vein, arterial, 
and microvascular cells all have different morphologies. For example, there are 
intercellular gaps in arterial and venous segments but not in capillary segments. This 
indicates that cells would adhere and extravasate different in these sections of the 
circulatory system[71]. A microvascular endothelial cell line such as Human Dermal 
Microvascular Endothelial Cells, HMVEC, and an arterial cell line such as Human 
Pulmonary Artery Endothelial cells, HPAEC, should be utilized in repeated experiments 
to determine if the effects of CD151 and β1 on adhesion and migration vary depending on 
endothelial cell line.  
5-5.4 Investigating the Effects of Smooth Muscle Cells 
In the migration studies described here, it was determined how the matrix and how a 
monolayer of endothelial cells affected migration. However, the endothelial cells of the 
veins and arteries are surrounded by smooth muscle cells which would add another layer 
of resistance and could greatly affect how cells extravasate. Therefore, transwell studies 
need to be repeated using a smooth muscle cell line such as Primary Aortic Smooth 
Muscle cells.  
5-5.5 Determining the Threshold of Detachment 
At 2 dyne/cm
2
 there was no significance in detachment. However, at a shear stress of 8 
dyne/cm
2
, there the knocked down cells detached significantly more than the control 
cells. These shear stresses had been chosen as representative shear stresses of the venous 
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and arterial circulation. The shear stress in the venous circulation can range up to 4 
dyne/cm
2
, and the arterial circulation can range as low as 4 dyne/cm
2
.  Due to a gap of 6 
dyne/cm
2
, it is unknown at what threshold the shear stress is high enough to cause 
significant detachment. Ideally, the next set of experiments should be conducted at 4 
dyne/cm
2
 since this is the overlapping shear stress for the venous and arterial circulation. 
5-5.6 Determining the Effects of Cell Cycle on Metastasis 
In many of the transwell studies performed here, there were clusters of multiple cells. 
This indicates that either the cells had migrated through as a cluster, clustered after 
migration, or had divided and multiplied after migrating. As discussed earlier, since the 
imaging is performed in the plane parallel to migration, it is impossible to determine 
which is occurring using transwell assays alone. However, to give further insight on if the 
cells are multiplying, one of two modifications can be made to these studies. The first is 
to decrease the amount of time that the cells are allowed to migrate. For example, one 
common shorter endpoint for transwell assays is four hours. This would give the cells 
less time to undergo the cell cycle. The second option would be to synchronize the cells 
by culturing them in serum free media for 24 hours prior to seeding in the transwells. 
This would ensure that all cells are on the same phase of the cell cycle at the beginning of 
the experiments. Previous studies have shown that nearly all cells that adhere to a vessel 
wall are in the G1 phase while the cells that migrate across the vessel wall are in the G1/S 
transition indicating that cell cycle does play a role in these processes[72].  
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5-5.7 Alternative Transwell Assays 
Depending on how the transwell assay is preform, these studies can answer many 
different questions. In the studies that have been described here, we determined how 
CD151 and β1 effected random migration. However, to determine how these proteins 
effect directed migration, studies need to be performed in which serum free media is 
placed inside of the insert and media containing FBS is placed inside of the well. This 
concentration difference will act to polarize the cells and enhance migration.  
Alternative migration studies cold also be performed in which the HUVECs are seeded 
on the opposite side of the membrane. This would mimic the configuration of  
intravasation rather than extravasation.  
5-5.8 Determining the Effects of shRNA Gene Silencing vs Antibodies 
There are two ways to negate the effects of a protein in a process. The first is through 
gene silencing. As mentioned earlier, shRNA was used to knock down the genes for 
CD151 and β1 in the studies that were described there. There is also the method of siRNA 
(small interfacing RNA) to knock down genes. These methods both work by degrading 
the target mRNA (messenger RNA). The second method to negate the effects of a protein 
is through an antibody. An antibody will physically bind to the protein of interest and 
physically prevent the protein from interacting with its environment. These methods will 
affect the cell and its adhesion differently. For example, the loss of a protein could cause 
structural differences in the cell while the antibody could also block other proteins that 
are not the targeted protein. Doing comparison studies would determine if CD151 and β1 
were the cause of decreased adhesion or if it was due to an unknown side effect of the 
gene silencing.  
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List of Abbreviations 
ATCC  American Type Cell Culture 
BME   Basement Membrane Extract 
CAM  Chick Chorioallantoic Membrane  
CD151  Cluster of Differentiation 151 
CXCL12  Chemokine (C-X-C motif) ligand 12 
CXCR4  chemokine receptor type 4 
CXCR7  chemokine receptor type 7 
DMEM  Dulbecco’s Modified Eagle Medium 
DiI   1,1'-Dioctadecyl-3,3,3',3'-Tetramethylindocarbocyanine Perchlorate 
DiO   3,3'-Dioctadecyloxacarbocyanine Perchlorate 
EBM   Endothelial Growth Basal Medium 
EDTA  Trypsin Ethylenediaminetetraacid Acid 
EGF   Epidermal Growth Factor 
EGM-2  Endothelial Growth Medium 2 
EMT  Epithelial to Mesenchymal Transition 
FBS   Fetal Bovine Serum 
GFP   Green Florescent Protein 
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HGF   Hepatocyte Growth Factor 
HUVEC  Human Umbicial Vein Endothelial Cell 
ICAM-1  Intercellular Adhesion Molecule 
IgG   Immunoglubulin G 
LLC  Lewis lung carcinoma  
MLEC  Mouse lung endothelial cells 
mRNA  Messanger RNA 
PBS   Phosphate-buffered saline 
PECAM-1  Platelet endothelial cell adhesion molecule 
PMA   phorbol 12-myristate 13-acetate 
60 
shRNA small/short hairpin RNA 
siRNA small interfacing RNA  
TGF-β Transforming Growth Factor 
TNF-α Tumor Necrosis Factor-α 
TNS Trypsin Neutralizing Solution 
61 
References 
1. Jemal, A., E. Ward, and M. Thun, Declining death rates reflect progress against
cancer. PLoS One, 2010. 5(3): p. e9584.
2. Hemler, M.E., Tetraspanin functions and associated microdomains. Nat Rev Mol
Cell Biol, 2005. 6(10): p. 801-811.
3. Lebrun, J.-J., The Dual Role of TGF in Human Cancer: From Tumor Suppression
to Cancer Metastasis. ISRN Molecular Biology, 2012. 2012: p. 28.
4. Wirtz, D., K. Konstantopoulos, and P.C. Searson, The physics of cancer: the role
of physical interactions and mechanical forces in metastasis. Nat Rev Cancer,
2011. 11(7): p. 512-522.
5. Yang, X.H., et al., CD151 Accelerates Breast Cancer by Regulating α6 Integrin
Function, Signaling, and Molecular Organization. Cancer Research, 2008. 68(9):
p. 3204-3213.
6. Tokuhara, T., et al., Clinical Significance of CD151 Gene Expression in Non-
Small Cell Lung Cancer. Clinical Cancer Research, 2001. 7(12): p. 4109-4114.
7. Ang, J., et al., CD151 Protein Expression Predicts the Clinical Outcome of Low-
Grade Primary Prostate Cancer Better than Histologic Grading: A New
Prognostic Indicator? Cancer Epidemiology Biomarkers & Prevention, 2004.
13(11): p. 1717-1721.
8. Jeon, J.S., et al., In Vitro Model of Tumor Cell Extravasation. PLoS ONE, 2013.
8(2): p. e56910.
9. Siegel, R., D. Naishadham, and A. Jemal, Cancer statistics, 2013. CA: A Cancer
Journal for Clinicians, 2013. 63(1): p. 11-30.
10. Weigelt, B., J.L. Peterse, and L.J. van't Veer, Breast cancer metastasis: markers
and models. Nat Rev Cancer, 2005. 5(8): p. 591-602.
11. Weber, G.F., Why does cancer therapy lack effective anti-metastasis drugs?
Cancer Letters, 2013. 328(2): p. 207-211.
12. Nishida, N., et al., Angiogenesis in Cancer. Vascular Health and Risk
Management, 2006. 2(3): p. 213-219.
13. Folkman, J., Tumor Angiogenesis: A Possible Control Point in Tumor Growth.
Annals of Internal Medicine, 1975. 82(1): p. 96-100.
14. Carmeliet, P. and R.K. Jain, Angiogenesis in cancer and other diseases. Nature,
2000. 407(6801): p. 249-257.
15. Deryugina, E.I. and J.P. Quigley, Tumor angiogenesis: MMP-mediated induction
of intravasation- and metastasis-sustaining neovasculature. Matrix Biology,
2015. 44–46: p. 94-112.
16. Weidner, N., et al., Tumor Angiogenesis and Metastasis — Correlation in
Invasive Breast Carcinoma. New England Journal of Medicine, 1991. 324(1): p.
1-8.
17. Kalluri, R. and R.A. Weinberg, The basics of epithelial-mesenchymal transition.
The Journal of Clinical Investigation, 2009. 119(6): p. 1420-1428.
18. Hart, I.R., 'Seed and soil' revisited: mechanisms of site-specific metastasis.
Cancer Metastasis Rev, 1982. 1(1): p. 5-16.
19. Koop, S., et al., Independence of metastatic ability and extravasation: metastatic
ras-transformed and control fibroblasts extravasate equally well. Proceedings of
62 
 
the National Academy of Sciences of the United States of America, 1996. 93(20): 
p. 11080-11084. 
20. Reymond, N., B.B. d'Agua, and A.J. Ridley, Crossing the endothelial barrier 
during metastasis. Nat Rev Cancer, 2013. 13(12): p. 858-870. 
21. Chen, M.B., et al., Mechanisms of tumor cell extravasation in an in vitro 
microvascular network platform. Integr Biol (Camb), 2013. 5(10): p. 1262-71. 
22. Dustin, M.L. and T.A. Springer, Lymphocyte function-associated antigen-1 (LFA-
1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of at least 
three mechanisms for lymphocyte adhesion to cultured endothelial cells. The 
Journal of Cell Biology, 1988. 107(1): p. 321-331. 
23. Butler, L.M., H.M. McGettrick, and G.B. Nash, Static and Dynamic Assays of 
Cell Adhesion Relevant to the Vasculature, in Angiogenesis Protocols, C. Murray 
and S. Martin, Editors. 2009, Humana Press. p. 211-228. 
24. Prabhakarpandian, B., et al., Microfluidic devices for modeling cell-cell and 
particle-cell interactions in the microvasculature. Microvasc Res, 2011. 82(3): p. 
210-20. 
25. Moss, M.A. and K.W. Anderson, Adhesion of Cancer Cells to Endothelial 
Monolayers: A Study of Initial Attachment Versus Firm Adhesion. The Journal of 
Adhesion, 2000. 74(1-4): p. 19-40. 
26. Chung, S., et al., Cell migration into scaffolds under co-culture conditions in a 
microfluidic platform. Lab Chip, 2009. 9(2): p. 269-75. 
27. Riahi, R., et al., A microfluidic model for organ-specific extravasation of 
circulating tumor cells. Biomicrofluidics, 2014. 8(2): p. 024103. 
28. Reese, B.E., et al. Microfluidic device for studying tumor cell extravasation in 
cancer metastasis. in Biomedical Sciences and Engineering Conference (BSEC), 
2010. 2010. 
29. Heyder, C., et al., Realtime visualization of tumor cell/endothelial cell 
interactions during transmigration across the endothelial barrier. Journal of 
Cancer Research and Clinical Oncology, 2002. 128(10): p. 533-538. 
30. Lawrence, M.B., L.V. McIntire, and S.G. Eskin, Effect of flow on 
polymorphonuclear leukocyte/endothelial cell adhesion. Blood, 1987. 70(5): p. 
1284-90. 
31. Moss, M.A., S. Zimmer, and K.W. Anderson, Role of metastatic potential in the 
adhesion of human breast cancer cells to endothelial monolayers. Anticancer Res, 
2000. 20(3a): p. 1425-33. 
32. Sia, S.K. and G.M. Whitesides, Microfluidic devices fabricated in 
Poly(dimethylsiloxane) for biological studies. ELECTROPHORESIS, 2003. 
24(21): p. 3563-3576. 
33. De Nevers, N., Fluid Mechanics for Chemical Engineers. 2004: McGraw-Hill 
Higher Education. 
34. Papaioannou, T.G. and C. Stefanadis, Vascular wall shear stress: basic principles 
and methods. Hellenic J Cardiol, 2005. 46(1): p. 9-15. 
35. Karamatic Crew, V., et al., CD151, the first member of the tetraspanin (TM4) 
superfamily detected on erythrocytes, is essential for the correct assembly of 
human basement membranes in kidney and skin. Blood, 2004. 104(8): p. 2217-23. 
63 
 
36. Kagan, A., et al., Occurrence of hereditary nephritis, pretibial epidermolysis 
bullosa and beta-thalassemia minor in two siblings with end-stage renal disease. 
Nephron, 1988. 49(4): p. 331-2. 
37. Testa, J.E., et al., Eukaryotic expression cloning with an antimetastatic 
monoclonal antibody identifies a tetraspanin (PETA-3/CD151) as an effector of 
human tumor cell migration and metastasis. Cancer Res, 1999. 59(15): p. 3812-
20. 
38. Zijlstra, A., et al., The inhibition of tumor cell intravasation and subsequent 
metastasis through the regulation of in vivo tumor cell motility by the tetraspanin 
CD151. Cancer cell, 2008. 13(3): p. 221-234. 
39. J.F. Haeuw, L.G., C. Bailly, N. Corvaia, Tetraspanin CD151 as a target for 
antibody-based cancer immunotherapy. Biochem Soc Trans, 2011. 39(2). 
40. Voss, M.A., et al., Tetraspanin CD151 is a novel prognostic marker in poor 
outcome endometrial cancer. Br J Cancer, 2011. 104(10): p. 1611-1618. 
41. Yue, S., W. Mu, and M. Zöller, Tspan8 and CD151 promote metastasis by 
distinct mechanisms. European Journal of Cancer, 2013. 49(13): p. 2934-2948. 
42. Takeda, Y., et al., Deletion of tetraspanin Cd151 results in decreased pathologic 
angiogenesis in vivo and in vitro. Blood, 2007. 109(4): p. 1524-32. 
43. Takeda, Y., et al., Diminished metastasis in tetraspanin CD151-knockout mice. 
Blood, 2011. 118(2): p. 464-72. 
44. Deng, X., et al., Integrin-Associated CD151 Drives ErbB2-Evoked Mammary 
Tumor Onset and Metastasis. Neoplasia, 2012. 14(8): p. 678-IN3. 
45. Deng, X., et al., Integrin-associated CD151 drives ErbB2-evoked mammary 
tumor onset and metastasis. Neoplasia, 2012. 14(8): p. 678-89. 
46. Cordes, N. and C.C. Park, beta1 integrin as a molecular therapeutic target. Int J 
Radiat Biol, 2007. 83(11-12): p. 753-60. 
47. Akiyama, S., K. Olden, and K. Yamada, Fibronectin and integrins in invasion 
and metastasis. Cancer and Metastasis Reviews, 1995. 14(3): p. 173-189. 
48. Brakebusch, C., et al., Genetic analysis of beta1 integrin function: confirmed, new 
and revised roles for a crucial family of cell adhesion molecules. J Cell Sci, 1997. 
110 ( Pt 23): p. 2895-904. 
49. Zetter, B.R., Adhesion molecules in tumor metastasis. Semin Cancer Biol, 1993. 
4(4): p. 219-29. 
50. Fujita, S., et al., Alteration of expression in integrin beta 1-subunit correlates with 
invasion and metastasis in colorectal cancer. Cancer Lett, 1995. 91(1): p. 145-9. 
51. Elliott, B.E., et al., Anti-beta 1 integrin IgG inhibits pulmonary macrometastasis 
and the size of micrometastases from a murine mammary carcinoma. Cell Adhes 
Commun, 1994. 1(4): p. 319-32. 
52. Cannistra, S.A., et al., Expression and Function of β1 and αvβ3 Integrins in 
Ovarian Cancer. Gynecologic Oncology, 1995. 58(2): p. 216-225. 
53. Strobel, T. and S.A. Cannistra, Beta1-integrins partly mediate binding of ovarian 
cancer cells to peritoneal mesothelium in vitro. Gynecol Oncol, 1999. 73(3): p. 
362-7. 
54. Chen, M.B., et al., Abstract 306: Role of tumor beta-1 integrin in the tumor cell 
extravasation cascade. Cancer Research, 2015. 75(15 Supplement): p. 306. 
64 
 
55. Schwartz, M.A. and A.R. Horwitz, Integrating Adhesion, Protrusion, and 
Contraction during Cell Migration. Cell, 2006. 125(7): p. 1223-1225. 
56. Horwitz, R. and D. Webb, Cell migration. Current Biology, 2003. 13(19): p. 
R756-R759. 
57. Lauffenburger, D.A. and A.F. Horwitz, Cell Migration: A Physically Integrated 
Molecular Process. Cell, 1996. 84(3): p. 359-369. 
58. Huttenlocher, A., R.R. Sandborg, and A.F. Horwitz, Adhesion in cell migration. 
Current Opinion in Cell Biology, 1995. 7(5): p. 697-706. 
59. Caswell, P. and J. Norman, Endocytic transport of integrins during cell migration 
and invasion. Trends in Cell Biology, 2008. 18(6): p. 257-263. 
60. Yauch, R.L., et al., Highly Stoichiometric, Stable, and Specific Association of 
Integrin α3β1 with CD151 Provides a Major Link to Phosphatidylinositol 4-
Kinase, and May Regulate Cell Migration. Molecular Biology of the Cell, 1998. 
9(10): p. 2751-2765. 
61. Sterk, L.M., et al., Association of the tetraspanin CD151 with the laminin-binding 
integrins alpha3beta1, alpha6beta1, alpha6beta4 and alpha7beta1 in cells in 
culture and in vivo. J Cell Sci, 2002. 115(Pt 6): p. 1161-73. 
62. Serru, V., et al., Selective tetraspan-integrin complexes (CD81/alpha4beta1, 
CD151/alpha3beta1, CD151/alpha6beta1) under conditions disrupting tetraspan 
interactions. Biochemical Journal, 1999. 340(Pt 1): p. 103-111. 
63. Nishiuchi, R., et al., Potentiation of the ligand-binding activity of integrin α3β1 
via association with tetraspanin CD151. Proceedings of the National Academy of 
Sciences of the United States of America, 2005. 102(6): p. 1939-1944. 
64. Scales, T.M., et al., alpha3beta1 integrins regulate CD151 complex assembly and 
membrane dynamics in carcinoma cells within 3D environments. Oncogene, 
2013. 32(34): p. 3965-79. 
65. Zoller, M., Tetraspanins: push and pull in suppressing and promoting metastasis. 
Nat Rev Cancer, 2009. 9(1): p. 40-55. 
66. Devbhandari, R.P., et al., Profiling of the Tetraspanin CD151 Web and 
Conspiracy of CD151/Integrin β1 Complex in the Progression of Hepatocellular 
Carcinoma. PLoS ONE, 2011. 6(9): p. e24901. 
67. Vigetti, D., et al., Matrix metalloproteinase 2 and tissue inhibitors of 
metalloproteinases regulate human aortic smooth muscle cell migration during in 
vitro aging. FASEB J, 2006. 20(8): p. 1118-30. 
68. Wang, C.M.X.-F., In Vitro Assays for the Extracellular Matrix Protein-Regulated 
Extravasation Process. Cold Spring Harb Protoc, 2008. 
69. Zhang, Q., T. Liu, and J. Qin, A microfluidic-based device for study of 
transendothelial invasion of tumor aggregates in realtime. Lab Chip, 2012. 
12(16): p. 2837-42. 
70. Holliday, D.L. and V. Speirs, Choosing the right cell line for breast cancer 
research. Breast Cancer Research : BCR, 2011. 13(4): p. 215-215. 
71. Shepro, D., Microvascular Research: Biology and Pathology. 2005: Academic. 
72. Sakaue-Sawano, A., et al., Visualizing spatiotemporal dynamics of multicellular 
cell-cycle progression. Cell, 2008. 132(3): p. 487-98. 
 
65 
Vita 
Rachel Renée Essex 
Born  Columbus, IN 
Education 
B.S. Degree in Chemical Engineering     2013 
Rose-Hulman Institute of Technology 
Minored in German and Applied Biologly; 
Graduate Cum Laude with 3.44 G.P.A 
Career History 
REU Particpant, University of Illinois at Chicago     2012 
College ProgramParticpant, Walt Disney World Resort    2011 
Tutor, Rose-Hulman Homework Hotline                 2009-2013 
